Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell P...
May 15 2019 - 8:00AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle,
WA, (NASDAQ:ALPN), a leading immunotherapy company focused on
developing treatments for autoimmune diseases and cancer, today
announced a collaboration and license agreement to develop
next-generation SPEAR T-cell products which incorporate Alpine’s
secreted and transmembrane immunomodulatory protein (termed SIP™
and TIP™) technology. This collaboration will further enhance
Adaptimmune’s efforts to design and develop next-generation SPEAR
T-cell therapies.
“SPEAR T-cell therapies have demonstrated clinical promise for
the treatment of solid tumors. Based on knowledge emerging from
translational research of resistance mechanisms, we will start our
first next-gen clinical study with ADP-A2M4CD8 in the second half
of 2019,” said Rafael Amado, Adaptimmune’s President of R&D.
“We are very excited to begin this collaboration with Alpine which
complements our research on next-generation SPEAR T-cells. We
believe that Alpine’s platform technology could engage further
rapid and flexible immunomodulatory mechanisms, which would enable
the development of future next-generation SPEAR T-cells with
enhanced antitumor potential.”
"Our directed evolution platform has successfully generated many
unique, multi-functional protein domains designed to favorably
modulate the tumor microenvironment via validated immune targets,”
said Stanford Peng, MD PhD, Alpine’s President and Head of Research
& Development. “We look forward to working with Adaptimmune to
develop next-generation SPEAR T-cell therapies to achieve improved
clinical outcomes.”
Alpine and Adaptimmune will collaborate on a specified number of
programs to develop SIP and TIP candidates with tailored affinities
and modulatory activities that may enhance the anti-tumor responses
seen with Adaptimmune’s SPEAR T-cells.
For each program, Adaptimmune has an option to take a worldwide
exclusive license for development and commercialization of SPEAR
T-cell products incorporating the developed SIP or TIP candidate
for the treatment of cancer.
Under the terms of the collaboration agreement, Adaptimmune will
provide an upfront payment and research funding for ongoing
programs. In addition, Alpine may be eligible for downstream
development and commercialization milestones up to $288M, if all
pre-specified milestones for each program are achieved.
Alpine will receive low-single digit royalties on worldwide net
sales of the applicable products.
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products for cancer patients. The
Company’s unique SPEAR (Specific Peptide Enhanced Affinity
Receptor) T‑cell platform enables the engineering of T-cells to
target and destroy cancer across multiple solid tumors. For more
information, please visit http://www.adaptimmune.com.
About Alpine Immune Sciences, Inc.Alpine Immune
Sciences, Inc. is committed to leading a new wave of functional
immune therapeutics. Alpine is employing directed evolution to
create potentially powerful multifunctional immunotherapies to
improve patients’ lives. Alpine has two lead programs. The first,
ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28
antagonist, engineered to reduce pathogenic immune responses. The
second, ALPN-202 for cancer, is a dual PD-L1/CTLA-4 antagonist and
PD-L1-dependent CD28 costimulator intended to combine checkpoint
inhibition with T cell costimulation – an approach currently absent
from approved checkpoint therapies. Alpine is backed by world-class
research and development capabilities, a highly-productive
scientific platform, and a proven management team. For more
information, visit www.alpineimmunesciences.com.
Forward-Looking Statements AdaptimmuneThis
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
on May 6, 2019, and our other SEC filings. The forward-looking
statements contained in this press release speak only as of the
date the statements were made and we do not undertake any
obligation to update such forward-looking statements to reflect
subsequent events or circumstances.
Forward-Looking Statements AlpineThis release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are not based on
historical fact and include statements regarding our platform
technology and potential therapies, the potential future
development plans of our and our collaborators’ product candidates
and our and our collaborators’ ability to successfully develop and
achieve milestones in development programs. Forward-looking
statements generally include statements that are predictive in
nature and depend upon or refer to future events or conditions, and
include words such as “may,” “will,” “should,” “would,” “expect,”
“plan,” “intend,” and other similar expressions among others. These
forward-looking statements are based on current assumptions that
involve risks, uncertainties and other factors that may cause
actual results, events or developments to be materially different
from those expressed or implied by such forward-looking statements.
These risks and uncertainties, many of which are beyond our
control, include, but are not limited to: clinical trials may not
demonstrate safety and efficacy of any of our or our collaborators’
product candidates; our ongoing discovery and pre-clinical efforts
may not yield additional product candidates; our discovery-stage
and pre-clinical programs may not advance into the clinic or result
in approved products; any of our or our collaborators’ product
candidates may fail in development, may not receive required
regulatory approvals, or may be delayed to a point where they are
not commercially viable; we may not achieve additional milestones
in our proprietary or partnered programs; the impact of
competition; adverse conditions in the general domestic and global
economic markets; as well as the other risks identified in our
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof and we
undertake no obligation to update forward-looking statements, and
readers are cautioned not to place undue reliance on such
forward-looking statements.
“Transmembrane Immunomodulatory Protein", "TIP", "Secreted
Immunomodulatory Protein", "SIP" "Variant Ig Domain", "vIgD", and
the Alpine logo are registered trademarks or trademarks of Alpine
Immune Sciences, Inc. in various jurisdictions.
Adaptimmune Contacts:
Media Relations:Sébastien Desprez – VP,
Communications and Investor RelationsT: +44 1235 430 583M: +44 7718
453 176 Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D. –
Senior Director, Investor RelationsT: +1 215 825 9310M: +1 215 460
8920Juli.Miller@adaptimmune.com
Alpine Contacts:
Investor Relations:Pure CommunicationsCourtney
Dugan, 212-257-6723cdugan@purecommunications.com
Media Relations:Pure CommunicationsJennifer
Paganelli, 347-658-8290jpaganelli@purecommunications.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Sep 2023 to Sep 2024